Companies › RANI Therapeutics
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PG-102 Tumor necrosis factor receptor superfamily member 5 inhibitor | CD40 | Phase 1 | Obesity; Type 2 Diabetes Mellitus (T2DM) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06712615 | PG-102 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Oct 2025 |
| NCT06891287 | PG-102 | Phase 1 | Obesity | Metabolic and endocrine | Dec 2026 |
Cash of $4m on 2026-09-30; operating cash outflow about $31m a year; runway about 1 months at that burn, to Nov 2026
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AbbVie Xencor Genmab Roche Akamis Bio Alligator Bioscience Veloxis Pharmaceuticals Novartis
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.